Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep 25;14(10):970.
doi: 10.3390/ph14100970.

Anticancer Drug-Induced Cardiotoxicity: Insights and Pharmacogenetics

Archana Adhikari  1 , Syed Mohammed Basheeruddin Asdaq  2 , Maitham A Al Hawaj  3 , Manodeep Chakraborty  1 , Gayatri Thapa  1 , Nihar Ranjan Bhuyan  4 , Mohd Imran  5 , Mohammed Kanan Alshammari  6 , Mohammed M Alshehri  7 , Aishah Ali Harshan  8 , Abeer Alanazi  9 , Bushra Dhuhayyan Alhazmi  10 , Nagaraja Sreeharsha  11   12
Affiliations
Review

Anticancer Drug-Induced Cardiotoxicity: Insights and Pharmacogenetics

Archana Adhikari et al. Pharmaceuticals (Basel). .

Abstract

The advancement in therapy has provided a dramatic improvement in the rate of recovery among cancer patients. However, this improved survival is also associated with enhanced risks for cardiovascular manifestations, including hypertension, arrhythmias, and heart failure. The cardiotoxicity induced by chemotherapy is a life-threatening consequence that restricts the use of several chemotherapy drugs in clinical practice. This article addresses the prevalence of cardiotoxicity mediated by commonly used chemotherapeutic and immunotherapeutic agents. The role of susceptible genes and radiation therapy in the occurrence of cardiotoxicity is also reviewed. This review also emphasizes the protective role of antioxidants and future perspectives in anticancer drug-induced cardiotoxicities.

Keywords: anticancer drugs; cardiotoxicity; chemotherapeutic agent; pharmacogenetics; radiation therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The mechanism of cyclophosphamide-mediated cardiac toxicity.
Figure 2
Figure 2
Mode of action of trastuzumab and its cardiotoxicity induction.
Figure 3
Figure 3
Diagrammatic representation of two major mechanisms of 5-fluorouracil-induced cardiotoxicity.
Figure 4
Figure 4
Clinical manifestation of CRS-related toxicities.
See this image and copyright information in PMC

References

    1. Chaulin A.M., Abashina O.E., Duplyakov D.V. Pathophysiological mechanisms of cardiotoxicity in chemotherapeutic agents. Russ. Open Med. J. 2020;9:1–9. doi: 10.15275/rusomj.2020.0305. - DOI
    1. Moudgil R., Yeh E.T. Mechanisms of cardiotoxicity of cancer chemotherapeutic agents: Cardiomyopathy and beyond. Can. J. Cardiol. 2016;32:863–870. doi: 10.1016/j.cjca.2016.01.027. - DOI - PMC - PubMed
    1. Dong J., Chen H. Cardiotoxicity of anticancer therapeutics. Front. Cardiovasc. Med. 2018;7:5–9. doi: 10.3389/fcvm.2018.00009. - DOI - PMC - PubMed
    1. Grieve D.J., Davidson S.M. New insights into cardiotoxicity caused by chemotherapeutic agents: Editorial. Br. J. Pharmacol. 2017;174:3675–3676. doi: 10.1111/bph.14025. - DOI - PMC - PubMed
    1. Jain D., Aronow W. Cardiotoxicity of cancer chemotherapy in clinical practice. Hosp. Pract. 2019;47:6–15. doi: 10.1080/21548331.2018.1530831. - DOI - PubMed

LinkOut - more resources